Morgan Stanley Maintains Regeneron Pharmaceuticals(REGN.US) With Buy Rating, Maintains Target Price $1,183

Morgan Stanley analyst Terence Flynn maintains $Regeneron Pharmaceuticals(REGN.US)$ with a buy rating, and maintains the target price at $1,183.According to TipRanks data, the analyst has a success ra

Futu NewsJul 3 21:32 · Ratings

Buy Rating for Regeneron Pharmaceuticals Amidst EU Approval of Dupixent and Positive Market Outlook

TipRanksJul 3 21:25

Europe Approves Sanofi/Regeneron's Dupixent for 'Smoker's Lungs' A Month After US FDA Asks For Data

On Wednesday, the European Medicines Agency (EMA) approved Dupixent (dupilumab) as an add-on maintenance treatment for adults with uncontrolled chronic obstructive pulmonary disease (COPD) characteriz

BenzingaJul 3 20:55

Regeneron (REGN), SNY Win EC Approval for Dupixent for COPD

Yahoo FinanceJul 3 20:06

Regeneron, Sanofi Say Chronic Obstructive Pulmonary Disease Treatment Gains European Approval

Regeneron Pharmaceuticals (REGN) and Sanofi (SNY) said Wednesday the European Commission has approved Dupixent as an additional maintenance treatment for adults with uncontrolled chronic obstructive p

MT NewswiresJul 3 16:15

Sanofi and Regeneron Pharmaceuticals Got Approval From European Union

This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.

MarketWatchJul 3 14:42